Stockscreener 앱 받기
87.11
3.22%
-2.90
시간 외 거래:
87.11
전일 마감가:
$90.01
열려 있는:
$86.36
하루 거래량:
912.49K
Relative Volume:
0.96
시가총액:
$5.45B
수익:
$434.41M
순이익/손실:
$-128.05M
주가수익비율:
-41.28
EPS:
-2.11
순현금흐름:
$-250.52M
1주 성능:
-2.92%
1개월 성능:
-2.94%
6개월 성능:
-1.09%
1년 성능:
-5.55%
1일 변동 폭
$86.21
$89.14
1주일 범위
$84.55
$90.39
52주 변동 폭
$80.67
$121.90
Blueprint Medicines Corp Stock (BPMC) Company Profile
명칭
Blueprint Medicines Corp
전화
617-374-7580
주소
45 SIDNEY STREET, CAMBRIDGE, MA
BPMC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BPMC
Blueprint Medicines Corp
|
87.11 | 5.45B | 434.41M | -128.05M | -250.52M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-20 | 재개 | Morgan Stanley | Equal-Weight |
| 2025-03-18 | 개시 | Wolfe Research | Outperform |
| 2025-03-17 | 개시 | Jefferies | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-11-14 | 개시 | JP Morgan | Overweight |
| 2024-10-24 | 개시 | UBS | Neutral |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2024-05-06 | 업그레이드 | Leerink Partners | Underperform → Market Perform |
| 2023-10-27 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-08-21 | 재확인 | Needham | Buy |
| 2023-07-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-06-05 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2023-01-03 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-11-02 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-09-14 | 개시 | Berenberg | Buy |
| 2022-07-08 | 개시 | Oppenheimer | Outperform |
| 2022-06-27 | 개시 | Wells Fargo | Underweight |
| 2022-06-10 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-06-01 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-03-01 | 개시 | Citigroup | Neutral |
| 2022-02-17 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-01-25 | 업그레이드 | Stifel | Hold → Buy |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-09-30 | 재개 | Stifel | Hold |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-03-31 | 개시 | Credit Suisse | Neutral |
| 2020-12-03 | 개시 | Stifel | Hold |
| 2020-11-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-10-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-15 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-05 | 개시 | Barclays | Equal Weight |
| 2020-03-17 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2019-11-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-10-22 | 개시 | JMP Securities | Mkt Outperform |
| 2019-10-03 | 개시 | H.C. Wainwright | Buy |
| 2019-09-12 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-08-29 | 개시 | Piper Jaffray | Neutral |
| 2019-08-15 | 재개 | Raymond James | Mkt Perform |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2019-05-23 | 재개 | Goldman | Buy |
| 2019-04-03 | 개시 | Morgan Stanley | Overweight |
| 2018-09-25 | 개시 | Leerink Partners | Outperform |
| 2017-12-11 | 재확인 | Goldman | Buy |
모두보기
Blueprint Medicines Corp 주식(BPMC)의 최신 뉴스
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by Vanguard Group Inc. - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Corebridge Financial Inc. - The AM Reporter
Exclusive: Blueprint Medicines Leadership Takes Center Stage at Major Healthcare Conference - Stock Titan
Is Blueprint Medicines (BPMC) One of the Best Mid Cap Biotech Stocks to Buy? - Insider Monkey
Blueprint Medicines at H.C. Wainwright Conference: Strategic Pipeline Expansion - Investing.com
Blueprint Medicines at H.C. Wainwright Conference: Strategic Pipeline Expansion By Investing.com - Investing.com UK
Blueprint Medicines COO Christina Rossi sells shares worth $216,075 By Investing.com - Investing.com Canada
Blueprint Medicines COO Christina Rossi sells shares worth $216,075 - Investing.com India
Is Blueprint Medicines Corporation (BPMC) a Promising Biotech Stock According to Wall Street Analysts - Yahoo Finance
PNC Financial Services Group Inc. Boosts Stake in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Proficio Capital Partners LLC Makes New $1.01 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
The Analyst Verdict: Blueprint Medicines In The Eyes Of 14 Experts - Benzinga
Blueprint Medicines (BPMC): Among Stocks Insiders Are Selling In March - Insider Monkey
Morgan Stanley sets Blueprint Medicines stock at Equalweight, $100 target - Investing.com
Morgan Stanley sets Blueprint Medicines stock at Equalweight, $100 target By Investing.com - Investing.com UK
Blueprint Medicines’ SWOT analysis: stock poised for growth amid challenges - Investing.com
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Victory Capital Management Inc. - Defense World
Wolfe Research initiates Blueprint Medicines with Outperform rating - Investing.com
Blueprint Medicines (NASDAQ:BPMC) Now Covered by Jefferies Financial Group - Defense World
This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
241,966 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Purchased by Raymond James Financial Inc. - Defense World
Blueprint Medicines initiated with a Buy at Jefferies - TipRanks
Jefferies sets Blueprint Medicines stock Buy rating, $135 target - Investing.com
Jefferies sets Blueprint Medicines stock Buy rating, $135 target By Investing.com - Investing.com Philippines
Blueprint Medicines (NASDAQ:BPMC) Shares Down 1.6% – Here’s Why - Defense World
Blueprint Medicines director Jeffrey Albers sells $658,500 in stock By Investing.com - Investing.com Australia
Steward Partners Investment Advisory LLC Lowers Position in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines director Jeffrey Albers sells $658,500 in stock - Investing.com India
Charles Schwab Investment Management Inc. Purchases 7,165 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines’ SWOT analysis: strong Ayvakit sales drive stock outlook By Investing.com - Investing.com South Africa
Blueprint Medicines’ SWOT analysis: strong Ayvakit sales drive stock outlook - Investing.com
US Bancorp DE Sells 1,988 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Lifted by Bank of New York Mellon Corp - Defense World
Blueprint Medicines (NASDAQ:BPMC) Coverage Initiated at Scotiabank - Defense World
Blueprint Medicines CFO sells shares worth $469,219 By Investing.com - Investing.com South Africa
Proficio Capital Partners LLC Purchases Shares of 11,600 Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines CEO sells $1.43 million in stock By Investing.com - Investing.com Australia
Zacks Research Has Positive Outlook for BPMC Q1 Earnings - Defense World
Blueprint Medicines Stock: Executives Sell Shares Amid Growth - sharewise
Blueprint Medicines CMO Hewes L. Becker sells $890k in stock - Investing.com Canada
Blueprint Medicines EVP sells shares worth $467,265 By Investing.com - Investing.com South Africa
Blueprint Medicines CEO sells $1.43 million in stock - Investing.com
Blueprint Medicines EVP sells shares worth $467,265 - Investing.com India
Blueprint Medicines chief commercial officer Lee Philina sells $331,490 in stock - Investing.com
Blueprint Medicines CFO sells shares worth $469,219 - Investing.com
Blueprint Medicines Executives Sell Shares to Cover Tax Obligations - TradingView
Blueprint Medicines Corp (BPMC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):